5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome - A systematic review and meta-analysis

Haematologica

Volumn 95, Issue 2, 2010, Pages 303-310

  Gurion, Ronit ^a,b   Vidal, Liat ^a,b   Gafter Gvili, Anat ^a,b   Yeshurun, Yulia Belnikmoshe ^a,b   Raanani, Pia ^a,b   Shpilberg, Ofer ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

5 azacitidine; Decitabine; Hypomethylating agents; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYTARABINE;

CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; META ANALYSIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 76549092572     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.010611     Document Type: Review

References (35)

1. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
2. Nimer SD. Myelodysplastic syndromes. Blood. 2008;111(10):4841-51.
3. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2-deoxycytidine. J Biol Chem. 1982;257(4):2041-8.
4. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res. 2007; 13(16):1634-7.
5. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993; 7 (Suppl 1):21-9.
6. Silverman LR, Holland JF, Demakos EP. Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol. 1994;68:A12[Abstract].
7. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11(1):1-5.
8. Wijermans PW, Krulder JW, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Lowdose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-62.
9. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8): 1794-803.
10. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol. 2002;20(10):2429-40.
11. Higgins JPT, Green S. eds. Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008.] http://www.cochrane.org/resources/ handbook,5.0.1Sep2008.pdf.
12. Cheson BD, Greenberg P, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
13. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815-34.
14. Gryn J, Zeigler ZR, Shadduck RK, Lister J, Raymond JM, Sbeitan I, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res. 2002;26(10):893-7.
15. Lübbert M, Wijermans PW, Kunzmann R, Verhoef G, Bosly A, Ravoet C, et al. Cytogenetic responses in high-risk myelodysplastic syndrome following lowdose treatment with the DNA methylation inhibitor 5-aza-2′- deoxycytidine. Br J Haematol. 2001;114(2):349-57.
16. Müller-Thomas C, Schuster T, Peschel C, Götze KS. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol. 2009;88(3):213-9.
17. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49(4):690-5.
18. Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008;32(4):587-91.
19. Soriano AO, Yang H, Faderl S, Estrov Z, Giles F, Ravandi F, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007; 110(7):2302-8.
20. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer. 2007;109(6):1133-7.
21. Pitako JA, Haas PS, Van den Bosch J, Müller-Berndorff H, Kündgen A, Germing U, et al. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine. Ann Hematol. 2005; 84 (Suppl 1):25-31.
22. Rüter B, Wijermans PW, Lübbert M. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients. Cancer. 2006; 106(8):1744-50.
23. van den Bosch J, Lübbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 2004;28(8):785-90.
24. Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, et al. 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia. 1993; 7 (Suppl 1):30-5.
25. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol. 1991; 37(2):100-4.
26. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109(1):52-7.
27. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-903.
28. Wijermans PW, Suciu S, Baila L, Platzbecker U, Giagounidis A, Selleslag D, et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood (ASH Annual Meeting Abstracts). 2008; 112: 226[Abstract].
29. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higherrisk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
30. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes. v.1.2009. available at: www.nccn.org.
31. Kumar A, List AF, Mhaskar R, Djulbegovic B. Efficacy of Hypo-methylating agents in the treatment of myelodysplastic syndromes: a systematic review and metaanalysis of randomized controlled trials. Blood (ASH Annual Meeting Abstracts) 2008; 112: 3632[Abstract].
32. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12): 6361-9.
33. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2′- deoxycytidine induces p21WAF expression by demythylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114(5):683-95.
34. Link PA, Baer MR, James SR, Jones DA, Karpf AR. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008;68(22):9358-66.
35. Herman JG, Gore SD, Mufti GJ, Fenaux P, Santini V, Silverman LR, et al. Relationship among gene methylation, azacitidine treatment, and survival in patients with higherrisk myelodysplastic syndromes (MDS): results from the AZA-001 TRIAL. AACR Annual Meeting 2009;4746 [Abstract].